Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (1): 20-25.DOI: 10.3969/j.issn.1673-8640.2018.01.004
• Orginal Article • Previous Articles Next Articles
LIU Wenhui1, BAI Jin'e2, ZHANG Hui3
Received:
2017-05-05
Published:
2021-03-18
CLC Number:
LIU Wenhui, BAI Jin'e, ZHANG Hui. Relations of serum alanine aminotransferase and gamma-glutamyltransferase with type 2 diabetes mellitus[J]. Laboratory Medicine, 2018, 33(1): 20-25.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.01.004
组别 | 例数 | 年龄(岁) | 性别 | 高血压 [例(%)] | 吸烟 [例(%)] | 饮酒 [例(%)] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | |||||||||||
T2DM组 | 238 | 53.95±7.76 | 133(10.17) | 105(8.15) | 85(35.71) | 52(21.84) | 51(21.43) | |||||
对照组 | 2 359 | 53.95±7.76 | 1 176(89.83) | 1 183(91.85) | 422(17.89) | 445(19.05) | 607(25.73) | |||||
组别 | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | Glu (mmol/L) | TC(mmol/L) | |||||
T2DM组 | 202(84.87) | 39(16.39) | 25.04±3.53 | 17.41±3.02 | 10.88±1.73 | 7.81±0.52 | 5.04±1.08 | |||||
对照组 | 2 215(93.90) | 23(9.74) | 23.57±3.34 | 16.52±3.01 | 10.33±1.63 | 6.47±0.63 | 4.87±0.94 | |||||
组别 | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | ALT(U/L) | GGT(U/L) | |||||||
T2DM组 | 1.53(1.09~2.02) | 1.38±0.39 | 3.14±0.87 | 23.0(17.0~32.0) | 19.0(13.0~26.5) | |||||||
对照组 | 1.32(0.97~1.84) | 1.46±0.41 | 3.02±0.82 | 20.0(15.0~26.0) | 17.0(13.0~26.0) |
组别 | 例数 | 年龄(岁) | 性别 | 高血压 [例(%)] | 吸烟 [例(%)] | 饮酒 [例(%)] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | |||||||||||
T2DM组 | 238 | 53.95±7.76 | 133(10.17) | 105(8.15) | 85(35.71) | 52(21.84) | 51(21.43) | |||||
对照组 | 2 359 | 53.95±7.76 | 1 176(89.83) | 1 183(91.85) | 422(17.89) | 445(19.05) | 607(25.73) | |||||
组别 | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | Glu (mmol/L) | TC(mmol/L) | |||||
T2DM组 | 202(84.87) | 39(16.39) | 25.04±3.53 | 17.41±3.02 | 10.88±1.73 | 7.81±0.52 | 5.04±1.08 | |||||
对照组 | 2 215(93.90) | 23(9.74) | 23.57±3.34 | 16.52±3.01 | 10.33±1.63 | 6.47±0.63 | 4.87±0.94 | |||||
组别 | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | ALT(U/L) | GGT(U/L) | |||||||
T2DM组 | 1.53(1.09~2.02) | 1.38±0.39 | 3.14±0.87 | 23.0(17.0~32.0) | 19.0(13.0~26.5) | |||||||
对照组 | 1.32(0.97~1.84) | 1.46±0.41 | 3.02±0.82 | 20.0(15.0~26.0) | 17.0(13.0~26.0) |
组别 | 例数 | 年龄(岁) | 性别 | 高血压[例(%)] | 吸烟[例(%)] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | ||||||||||
Q1组 | 640 | 53.00±3.89 | 310(48.44) | 330(51.56) | 93(14.53) | 140(21.88) | |||||
Q2组 | 659 | 53.75±3.57 | 335(50.83) | 324(49.17) | 122(18.51) | 128(19.42) | |||||
Q3组 | 653 | 54.08±3.78 | 343(52.53) | 310(47.47) | 139(21.29) | 139(21.29) | |||||
Q4组 | 645 | 54.50±3.82 | 321(49.77) | 324(50.23) | 153(23.72) | 153(23.72) | |||||
统计值 | 9.010 | 2.310 | 19.105 | 3.626 | |||||||
P值 | <0.001 | 0.509 | <0.001 | 0.305 | |||||||
组别 | 饮酒[例(%)] | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | |||||
Q1组 | 160(25.00) | 617(96.41) | 9(1.41) | 23.07±2.82 | 16.67±3.06 | 10.25±1.61 | |||||
Q2组 | 159(24.13) | 602(91.35) | 17(2.58) | 23.87±3.12 | 16.94±2.88 | 10.39±1.60 | |||||
Q3组 | 168(25.73) | 598(91.58) | 19(2.91) | 24.24±3.31 | 17.18±2.68 | 10.58±1.59 | |||||
Q4组 | 171(26.51) | 600(93.02) | 17(2.64) | 24.98±3.37 | 17.53±2.82 | 10.82±1.65 | |||||
统计值 | 1.017 | 16.321 | 3.634 | 8.120 | 8.330 | 10.990 | |||||
P值 | 0.784 | 0.001 | 0.304 | <0.001 | <0.001 | <0.001 | |||||
组别 | Glu(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | ||||||
Q1组 | 5.73±0.56 | 4.84±1.04 | 1.30±0.89 | 1.49±0.41 | 2.98±0.78 | ||||||
Q2组 | 5.80±0.58 | 4.92±1.11 | 1.36±0.77 | 1.41±0.38 | 3.06±0.80 | ||||||
Q3组 | 6.02±0.59 | 5.01±1.18 | 1.53±0.85 | 1.37±0.40 | 3.14±0.81 | ||||||
Q4组 | 6.17±0.60 | 5.03±1.12 | 1.65±1.15 | 1.35±0.42 | 3.19±0.80 | ||||||
统计值 | 11.190 | 8.210 | 9.790 | 8.310 | 12.070 | ||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.021 |
组别 | 例数 | 年龄(岁) | 性别 | 高血压[例(%)] | 吸烟[例(%)] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | ||||||||||
Q1组 | 640 | 53.00±3.89 | 310(48.44) | 330(51.56) | 93(14.53) | 140(21.88) | |||||
Q2组 | 659 | 53.75±3.57 | 335(50.83) | 324(49.17) | 122(18.51) | 128(19.42) | |||||
Q3组 | 653 | 54.08±3.78 | 343(52.53) | 310(47.47) | 139(21.29) | 139(21.29) | |||||
Q4组 | 645 | 54.50±3.82 | 321(49.77) | 324(50.23) | 153(23.72) | 153(23.72) | |||||
统计值 | 9.010 | 2.310 | 19.105 | 3.626 | |||||||
P值 | <0.001 | 0.509 | <0.001 | 0.305 | |||||||
组别 | 饮酒[例(%)] | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | |||||
Q1组 | 160(25.00) | 617(96.41) | 9(1.41) | 23.07±2.82 | 16.67±3.06 | 10.25±1.61 | |||||
Q2组 | 159(24.13) | 602(91.35) | 17(2.58) | 23.87±3.12 | 16.94±2.88 | 10.39±1.60 | |||||
Q3组 | 168(25.73) | 598(91.58) | 19(2.91) | 24.24±3.31 | 17.18±2.68 | 10.58±1.59 | |||||
Q4组 | 171(26.51) | 600(93.02) | 17(2.64) | 24.98±3.37 | 17.53±2.82 | 10.82±1.65 | |||||
统计值 | 1.017 | 16.321 | 3.634 | 8.120 | 8.330 | 10.990 | |||||
P值 | 0.784 | 0.001 | 0.304 | <0.001 | <0.001 | <0.001 | |||||
组别 | Glu(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | ||||||
Q1组 | 5.73±0.56 | 4.84±1.04 | 1.30±0.89 | 1.49±0.41 | 2.98±0.78 | ||||||
Q2组 | 5.80±0.58 | 4.92±1.11 | 1.36±0.77 | 1.41±0.38 | 3.06±0.80 | ||||||
Q3组 | 6.02±0.59 | 5.01±1.18 | 1.53±0.85 | 1.37±0.40 | 3.14±0.81 | ||||||
Q4组 | 6.17±0.60 | 5.03±1.12 | 1.65±1.15 | 1.35±0.42 | 3.19±0.80 | ||||||
统计值 | 11.190 | 8.210 | 9.790 | 8.310 | 12.070 | ||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.021 |
组别 | 例数 | 年龄(岁) | 性别 | 高血压[例(%)] | 吸烟[例(%)] | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | |||||||||||
Q1组 | 651 | 53.69±4.13 | 328(50.38) | 323(49.62) | 85(13.06) | 144(22.12) | ||||||
Q2组 | 647 | 54.28±3.80 | 330(51.00) | 317(49.00) | 101(15.61) | 133(20.56) | ||||||
Q3组 | 642 | 54.34±3.95 | 307(47.82) | 335(55.18) | 128(19.94) | 119(18.54) | ||||||
Q4组 | 657 | 54.21±4.01 | 344(52.36) | 313(47.64) | 193(29.38) | 101(15.37) | ||||||
统计值 | 9.120 | 2.814 | 64.295 | 10.750 | ||||||||
P值 | <0.001 | 0.421 | <0.001 | 0.013 | ||||||||
组别 | 饮酒[例(%)] | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | ||||||
Q1组 | 160(24.58) | 599(92.01) | 9(1.38) | 23.06±2.82 | 16.58±2.45 | 10.30±1.48 | ||||||
Q2组 | 153(23.65) | 601(92.89) | 15(2.32) | 23.96±3.14 | 16.72±2.33 | 10.35±1.44 | ||||||
Q3组 | 176(26.79) | 613(95.48) | 18(2.80) | 24.20±3.28 | 17.00±2.36 | 10.51±1.44 | ||||||
Q4组 | 171(26.51) | 604(91.93) | 20(3.04) | 24.93±3.35 | 17.30±2.33 | 10.89±1.42 | ||||||
统计值 | 2.791 | 8.272 | 5.428 | 8.390 | 7.930 | 11.270 | ||||||
P值 | 0.425 | 0.041 | 0.210 | <0.001 | <0.001 | <0.001 | ||||||
组别 | Glu(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | |||||||
Q1组 | 5.80±1.52 | 4.88±0.86 | 1.32±0.61 | 1.43±0.40 | 2.90±0.75 | |||||||
Q2组 | 5.89±1.67 | 4.94±0.85 | 1.45±0.73 | 1.41±0.43 | 3.02±0.76 | |||||||
Q3组 | 5.95±1.78 | 4.99±0.88 | 1.56±0.80 | 1.38±0.36 | 3.08±1.07 | |||||||
Q4组 | 6.15±1.82 | 5.04±0.92 | 1.68±1.14 | 1.37±0.39 | 3.15±0.79 | |||||||
统计值 | 13.040 | 9.220 | 13.150 | 8.960 | 11.390 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.001 |
组别 | 例数 | 年龄(岁) | 性别 | 高血压[例(%)] | 吸烟[例(%)] | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
男[例(%)] | 女[例(%)] | |||||||||||
Q1组 | 651 | 53.69±4.13 | 328(50.38) | 323(49.62) | 85(13.06) | 144(22.12) | ||||||
Q2组 | 647 | 54.28±3.80 | 330(51.00) | 317(49.00) | 101(15.61) | 133(20.56) | ||||||
Q3组 | 642 | 54.34±3.95 | 307(47.82) | 335(55.18) | 128(19.94) | 119(18.54) | ||||||
Q4组 | 657 | 54.21±4.01 | 344(52.36) | 313(47.64) | 193(29.38) | 101(15.37) | ||||||
统计值 | 9.120 | 2.814 | 64.295 | 10.750 | ||||||||
P值 | <0.001 | 0.421 | <0.001 | 0.013 | ||||||||
组别 | 饮酒[例(%)] | 锻炼[例(%)] | 糖尿病家族史 [例(%)] | BMI(kg/m2) | SBP(kPa) | DBP(kPa) | ||||||
Q1组 | 160(24.58) | 599(92.01) | 9(1.38) | 23.06±2.82 | 16.58±2.45 | 10.30±1.48 | ||||||
Q2组 | 153(23.65) | 601(92.89) | 15(2.32) | 23.96±3.14 | 16.72±2.33 | 10.35±1.44 | ||||||
Q3组 | 176(26.79) | 613(95.48) | 18(2.80) | 24.20±3.28 | 17.00±2.36 | 10.51±1.44 | ||||||
Q4组 | 171(26.51) | 604(91.93) | 20(3.04) | 24.93±3.35 | 17.30±2.33 | 10.89±1.42 | ||||||
统计值 | 2.791 | 8.272 | 5.428 | 8.390 | 7.930 | 11.270 | ||||||
P值 | 0.425 | 0.041 | 0.210 | <0.001 | <0.001 | <0.001 | ||||||
组别 | Glu(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | |||||||
Q1组 | 5.80±1.52 | 4.88±0.86 | 1.32±0.61 | 1.43±0.40 | 2.90±0.75 | |||||||
Q2组 | 5.89±1.67 | 4.94±0.85 | 1.45±0.73 | 1.41±0.43 | 3.02±0.76 | |||||||
Q3组 | 5.95±1.78 | 4.99±0.88 | 1.56±0.80 | 1.38±0.36 | 3.08±1.07 | |||||||
Q4组 | 6.15±1.82 | 5.04±0.92 | 1.68±1.14 | 1.37±0.39 | 3.15±0.79 | |||||||
统计值 | 13.040 | 9.220 | 13.150 | 8.960 | 11.390 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.001 |
组别 | 例数 | T2DM(例) | 模式 1 | 模式 2 |
---|---|---|---|---|
Q1组 | 640 | 11 | 1.00 | 1.00 |
Q2组 | 659 | 37 | 1.63(1.89~2.24) | 1.35(0.97~1.88) |
Q3组 | 653 | 83 | 1.71(1.18~2.35) | 1.48(0.92~1.99) |
Q4组 | 645 | 97 | 2.75(2.05~3.69) | 1.70(1.05~2.73) |
P值 | 0.000 | 0.005 |
组别 | 例数 | T2DM(例) | 模式 1 | 模式 2 |
---|---|---|---|---|
Q1组 | 640 | 11 | 1.00 | 1.00 |
Q2组 | 659 | 37 | 1.63(1.89~2.24) | 1.35(0.97~1.88) |
Q3组 | 653 | 83 | 1.71(1.18~2.35) | 1.48(0.92~1.99) |
Q4组 | 645 | 97 | 2.75(2.05~3.69) | 1.70(1.05~2.73) |
P值 | 0.000 | 0.005 |
组别 | 例数 | T2DM(例) | 模式 1 | 模式 2 |
---|---|---|---|---|
Q1组 | 651 | 15 | 1.00 | 1.00 |
Q2组 | 647 | 31 | 1.54(1.04~2.28) | 1.21(0.79~1.84) |
Q3组 | 642 | 74 | 1.40(1.22~2.11) | 1.14(1.02~1.65) |
Q4组 | 657 | 108 | 2.80(1.95~4.01) | 2.38(1.77~3.17) |
P值 | 0.000 | 0.003 |
组别 | 例数 | T2DM(例) | 模式 1 | 模式 2 |
---|---|---|---|---|
Q1组 | 651 | 15 | 1.00 | 1.00 |
Q2组 | 647 | 31 | 1.54(1.04~2.28) | 1.21(0.79~1.84) |
Q3组 | 642 | 74 | 1.40(1.22~2.11) | 1.14(1.02~1.65) |
Q4组 | 657 | 108 | 2.80(1.95~4.01) | 2.38(1.77~3.17) |
P值 | 0.000 | 0.003 |
[1] | XU Y,WANG L,HE J,et al.Prevalence and control of diabetes in Chinese adults[J]. JAMA,2013,310(9):948-959. |
[2] | HAZLEHURST J M,WOODS C,MARJOT T,et al.Non-alcoholic fatty liver disease and diabetes[J]. Metabolism,2016,65(8):1096-1108. |
[3] | ANSTEE Q M,TARGHER G,DAY C P.Progression of NAFLD to diabetes mellitus,cardiovascular disease or cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2013,10(6):330-344. |
[4] | 刘力生. 中国高血压防治指南2010[J]. 中华高血压杂志,2011,19(8):701-743. |
[5] | American Diabetes Association.Diagnosis and classification of diabetes mellitus[J]. Diabetes Care,2014,37(Suppl 1):S81-S90. |
[6] | SIDDIQUI M S,STERLING R K,LUKETIC V A,et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis[J].Gastroenterology,2013,145(6):1271-1279. e1-e3. |
[7] | LIU X,HAMNVIK O P,CHAMBERLAND J P,et al.Circulating alanine transaminase(ALT) and γ-glutamyl transferase(GGT),but not fetuin-A,are associated with metabolic risk factors,at baseline and at two-year follow-up:the prospective Cyprus Metabolism Study[J]. Metabolism,2014,63(6):773-782. |
[8] | BRADLEY R,FITZPATRICK A L,JENNY N S,et al.Associations between total serum GGT activity and metabolic risk:MESA[J]. Biomark Med,2013,7(5):709-721. |
[9] | SCHNEIDER A L,LAZO M,NDUMELE C E,et al.Liver enzymes,race,gender and diabetes risk:the Atherosclerosis Risk in Communities(ARIC) Study[J]. Diabet Med,2013,30(8):926-933. |
[10] | GAO F,PAN J M,HOU X H,et al.Liver enzymes concentrations are closely related to prediabetes:findings of the Shanghai Diabetes Study II(SHDS II)[J]. Biomed Environ Sci,2012,25(1):30-37. |
[11] | AHN H R,SHIN M H,NAM H S,et al.The association between liver enzymes and risk of type 2 diabetes:the Namwon study[J]. Diabetol Metab Syndr,2014,6(1):14. |
[12] | SAMUEL V T,LIU Z X,QU X,et al.Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease[J]. J Biol Chem,2004,279(31):32345-32353. |
[13] | ALDERETE T L,TOLEDO-CORRAL C M,DESAI P,et al. Liver fat has a stronger association with risk factors for type 2 diabetes in African-American compared with Hispanic adolescents[J]. J Clin Endocrinol Metab,2013,98(9):3748-3754. |
[14] | SUNG K C,JEONG W S,WILD S H,et al.Combined influence of insulin resistance,overweight/obesity,and fatty liver as risk factors for type 2 diabetes[J]. Diabetes Care,2012,35(4):717-722. |
[15] | SUNG K C,WILD S H,BYRNE C D.Resolution of fatty liver and risk of incident diabetes[J]. J Clin Endocrinol Metab,2013,98(9):3637-3643. |
[16] | 韩丽萍,孙蓓,李春君,等. 雷公藤多苷对糖尿病大鼠肝脏Toll样受体4介导免疫炎症信号通路的干预研究[J]. 中华糖尿病杂志,2016,8(3):152-156. |
[17] | BRADLEY R D,FITZPATRICK A L,JACOBS D R JR,et al.Associations between γ-glutamyltransferase(GGT) and biomarkers of atherosclerosis:the Multi-ethnic Study of Atherosclerosis(MESA)[J]. Atherosclerosis,2014,233(2):387-393. |
[18] | WANG X,BAO W,LIU J,et al.Inflammatory markers and risk of type 2 diabetes:a systematic review and meta-analysis[J]. Diabetes Care,2013,36(1):166-175. |
[19] | PEDICINO D,LIUZZO G,TROTTA F,et al.Adaptive immunity,inflammation,and cardiovascular complications in type 1 and type 2 diabetes mellitus[J]. J Diabetes Res,2013,2013:184258. |
[20] | UCAR H,GÜR M,GÖZÜKARA M Y,et al.Gamma glutamyl transferase activity is independently associated with oxidative stress rather than SYNTAX score[J]. Scand J Clin Lab Invest,2015,75(1):7-12. |
[21] | STADLER K.Oxidative stress in diabetes[J]. Adv Exp Med Biol,2012,771:272-287. |
[1] | LIANG Chaohui, ZHAO Fan, LIU Qianwen. Relationship between macrophage migration inhibitory factor and carotid vascular calcification in elderly patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2023, 38(5): 460-465. |
[2] | DENG Xu, ZHUANG Wenlong, XUE Hui, ZHU Shuqin, LI Ying. Relationship between neutrophil/lymphocyte ratio,fibrinogen and carotid intima-media thickness in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(4): 368-372. |
[3] | WU Ying, ZHANG Lihong, GAO Yin. Predictive value of high-density lipoprotein cholesterol on the risk of cerebral ischemic stroke in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(11): 1052-1056. |
[4] | QU Yuanqing, ZHAO Fan, YE Ailian, LI Lifeng, ZHAO Haitao, LI Huizhen, LIANG Zhuohui, LI Liang. Relationship between plasma omentin-1 level and metabolic clearance rate in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2022, 37(1): 28-31. |
[5] | ZHU Qinghua, WANG Weiwei, ZOU Guanghui, DONG Zhiwu. Combined detection of serum NGAL and Cys C in the diagnosis of early nephropathy in patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2021, 36(3): 281-284. |
[6] | ZHANG Qianjin, HU Jin'e, HU Yichuan, DING Ying, SHEN Yanqiu, CHEN Huiqin. Correlations of serum adipsin and Vit D levels with islet beta cell function and insulin sensitivity in patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2020, 35(9): 908-911. |
[7] | ZHOU Zhongwei, JU Huixiang, JIN Hao, CHEN Hongmei, SUN Mingzhong. Relationship between alpha 2-Heremans-Schmid glycoprotein to adiponectin ratio and type 2 diabetes mellitus complicated with metabolic syndrome [J]. Laboratory Medicine, 2020, 35(5): 414-419. |
[8] | ZUO Xuecan, CHU Yanling, LI Zhanping. Relationship between four coagulation factors and C peptide and IR in T2DM patients with microangiopathy [J]. Laboratory Medicine, 2020, 35(4): 327-328. |
[9] | LIU Xiaoni, WANG Ying, LI Taotao, MA Xiaomin, ZHAO Huanlao. Correlation of insulin resistance index and chronic inflammation index in type 2 diabetes mellitus patients with metabolic syndrome [J]. Laboratory Medicine, 2019, 34(9): 826-830. |
[10] | CHEN Yanwen, LIN Yao, XU Dongwen, MA Huili, LIU Ruilai, HU Yao. Role of urinary orosomucoid in monitoring kidney injury for type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2018, 33(12): 1108-1111. |
[11] | YU Xiaoxuan, OU Yuanzhu, TANG Liping, WANG Meijuan, LIU Wenbin, GE Danhong, WANG Ming. Analysis on the results of gamma-glutamyltransferase trueness verification survey in Shanghai [J]. Laboratory Medicine, 2018, 33(11): 1032-1035. |
[12] | LI Li, HU Juanyu, YU Zhengqing, MENG Hai. Correlation between serum interleukin 19 level and diabetic nephropathy [J]. Laboratory Medicine, 2017, 32(8): 691-694. |
[13] | OU Yuanzhu, YU Xiaoxuan, TANG Liping, JU Yi, WANG Meijuan, LIU Wenbin, JIN Zhonggan. Stability of alanine aminotransferase trueness control samples [J]. Laboratory Medicine, 2017, 32(8): 713-717. |
[14] | SUN Bin, WANG Shan, QIAN Jun, TANG Zhenhua. Prenatal screening for 63 109 pregnant women in Shanghai [J]. Laboratory Medicine, 2017, 32(5): 386-389. |
[15] | QIAN Dingliang, YAN Shaorong, LIU Lingyun. Soluble endothelial protein C receptor and soluble thrombomodulin in patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2017, 32(3): 208-209. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||